Cargando…

LB1528. Results from ACTIV-6: A Decentralized, Double-Blinded, Randomized, Placebo-Controlled Platform Trial of Repurposed Drugs for the Treatment of Mild-to-Moderate COVID-19

BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients with mild-to-moderate coronavirus 2019 (COVID-19) is unclear. Tolerability has also been identified as a potential limiting factor for 100 mg twice daily of fluvoxamine. We evaluated...

Descripción completa

Detalles Bibliográficos
Autor principal:	McCarthy, Matthew W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752734/ http://dx.doi.org/10.1093/ofid/ofac492.1874

Ejemplares similares

LB1528C. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
por: Naggie, Susanna
Publicado: (2022)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
por: Rossignol, Jean-François, et al.
Publicado: (2022)

ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19
Publicado: (2023)

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)

1528. Rates of Peripheral Blood Culture Contamination in an Urban Children’s Hospital
por: Tam, Derek, et al.
Publicado: (2019)

Spanish explorers in the Southern United States, 1528- 1543 : the Narrative of Alvar Nuñez Cabeza de Vaca /
Publicado: (1925)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
por: Dorostkar, Azadeh, et al.
Publicado: (2021)

The effect of Melissa officinalis syrup on patients with mild to moderate psoriasis: a randomized, double-blind placebo-controlled clinical trial
por: Yargholi, Alireza, et al.
Publicado: (2021)

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
por: Manomaipiboon, Anan, et al.
Publicado: (2022)

Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial
por: Kedia, Saurabh, et al.
Publicado: (2017)

1528. A Real-World Perspective on Treatment of CRE UTIs With Oral Agents
por: Babiker, Ahmed, et al.
Publicado: (2018)

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
por: Henderson, Samuel T, et al.
Publicado: (2009)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study
por: Marashian, Seyed Mehran, et al.
Publicado: (2022)

Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
por: Wada, Tatsuhiko, et al.
Publicado: (2023)

Platform Architecture for Decentralized Positioning Systems
por: Kasmi, Zakaria, et al.
Publicado: (2017)

La Catedral de San Cristóbal de Las Casas, Chiapas, 1528-1978 /
por: Flores Ruiz, Eduardo, 1890-1977
Publicado: (1978)

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
por: Gault, Laura M., et al.
Publicado: (2016)

A double-blind, placebo-controlled clinical trial to assess the effects of a combined nutraceutical on endothelial function in patients with mild-to-moderate hypercholesterolaemia
por: Pecchioli, Valerio, et al.
Publicado: (2020)

A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease
por: Dow, G.-S., et al.
Publicado: (2022)

Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial
por: Patankar, Suresh B., et al.
Publicado: (2022)

Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
Publicado: (2023)

Krill oil improved osteoarthritic knee pain in adults with mild to moderate knee osteoarthritis: a 6-month multicenter, randomized, double-blind, placebo-controlled trial
por: Stonehouse, Welma, et al.
Publicado: (2022)

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
por: Cadegiani, Flavio A, et al.
Publicado: (2021)

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hill, Joshua A, et al.
Publicado: (2021)

PO-1528 Mood disorder in cancer patients undergoing radiotherapy during the COVID-19 outbreak
por: Nardone, V., et al.
Publicado: (2021)

Effect of Linum usitatissimum L. (linseed) oil on mild and moderate carpal tunnel syndrome: a randomized, double-blind, placebo-controlled clinical trial
por: Hashempur, Mohammad Hashem, et al.
Publicado: (2014)

A Randomized, Double-Blind, Placebo-Controlled Study of a Novel Pantothenic Acid-Based Dietary Supplement in Subjects with Mild to Moderate Facial Acne
por: Yang, Michael, et al.
Publicado: (2014)

A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19
por: Nicastri, Emanuele, et al.
Publicado: (2022)

Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer’s disease: A randomized, double-blind, and placebo-controlled study
por: Akhgarjand, Camellia, et al.
Publicado: (2022)

Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial
por: Farahani, Ramin Hamidi, et al.
Publicado: (2023)

521. A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease
por: Dow, Geoffrey
Publicado: (2023)

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

The Effect of Intravenous Dexamethasone and Lidocaine on Propofol-Induced Vascular Pain: A Randomized Double-Blinded Placebo-Controlled Trial
por: Ahmad, Shireen, et al.
Publicado: (2013)

A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
por: Xu, Chongqing, et al.
Publicado: (2020)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_192gectvlhajdf7a2kg8vg4hb2